Researchers at the University of Canberra in Australia found that proton pump inhibitors (PPIs) such as Nexium, Prevacid and Prilosec are overused worldwide. Additionally, a separate study published in JAMA Otolaryngology–Head & Neck Surgery last month shows that dietary intervention may have as much benefit as PPIs in reducing laryngopharyngeal reflux (LPR) – a condition that occurs in a person who has gastroesophageal reflux disease (GERD), according to the Cleveland Clinic.
The findings published in JAMA show that patients with LPR who consumed a Mediterranean-style diet – 90 percent plant-based – and drank alkaline water, along with standard reflux precautions, experienced a reduction in their Reflux Symptom Index at a higher rate than patients treated only with PPIs. The diet-based approach provides other benefits as well, including “decreased risk for and improved control of cardiovascular disease, diabetes, stroke and cancer, and avoiding the risks of drug interaction or complication.”
This is good news for patients suffering from GERD and other acid-related disorders. For decades, PPIs have been prescribed to treat the disorders, but have also been linked to serious adverse side effects. Beasley Allen previously explained that mounting evidence links PPIs to Acute Interstitial Nephritis (AIN), which is inflammation in the spaces between the kidney tubules, and an increased risk of Acute Kidney Injury (AKI) or Acute Renal Failure, and Chronic Kidney Disease.
In fact, a multidistrict litigation (MDL) is pending in the U.S. District Court for the District of New Jersey with 209 cases pending against PPI manufacturers, the U.S. Judicial Panel on Multidistrict Litigation reports. Plaintiffs are suing the manufacturers after developing kidney damage linked to the use of PPIs, arguing that manufacturers should be held accountable for their failure to warn consumers about the drugs’ potential to cause kidney damage.
Defendant drugmakers include Takeda Pharmaceutical Co.; AstraZeneca; Pfizer Inc., (and its subsidiaries Wyeth Pharmaceuticals, Inc., Wyeth, LLC, and Wyeth-Ayerst Laboratories); Procter & Gamble Company; and Novartis Consumer Health, Inc. (and its subsidiaries Novartis Vaccines and Diagnostics, Inc. and Novartis Institute for Biomedical Research, Inc).
* * *
Lawyers in our firm’s Mass Torts Section are currently investigating cases for people who used PPIs and developed AIN, AKI or Acute Renal Failure, and Chronic Kidney Disease. If you would like more information, contact Tiffany Birley, at 800-898-2034 or by email at Tiffany.Birley@beasleyallen.com.
JAMA Otolaryngology–Head & Neck Surgery
U.S. Judicial Panel on Multidistrict Litigation